Reproductive endocrinology

Gonadal MRI in complete androgen insensitivity syndrome: pathologic correlation and low-risk features

J Clin Endocrinol MetabPublished Retrospective diagnostic accuracy study

Authors' conclusion

In postpubertal CAIS, homogeneous signal, absence of diffusion restriction, and low gonadal volume may identify gonads at low risk for macroscopic neoplasia and support conservative surveillance in selected individuals.

Study context

Population
Postpubertal individuals with molecularly confirmed complete androgen insensitivity syndrome (CAIS) who underwent preoperative pelvic MRI incl. diffusion-weighted imaging, followed by bilateral gonadectomy32 gonads
Participants
16 individuals
Comparison
Multiparametric gonadal MRI features vs histopathology after bilateral gonadectomy
Outcome
Absence of clinically relevant macroscopic gonadal neoplasia (histopathology)
Methodological detailsexpert radiologist review, histopathologic correlation
  • Expert radiologist review
  • Histopathologic correlation

Performance

As reported in the abstract

Absence of macroscopic neoplasia
Test or modelNPV
Homogeneous MRI signal100%
Absence of diffusion restriction100%

NPV

Homogeneous MRI signal100%
Absence of diffusion restriction100%
Macroscopic neoplasia identified (seminoma with adjacent germ cell neoplasia in situ, large-cell calcifying Sertoli cell tumor, serous borderline tumor of Müllerian type)
3 patients
Gonadal volume separated benign from neoplastic lesions: all non-neoplastic gonads
≤21.9 cm³
Gonadal volume: all neoplastic lesions
≥116.4 cm³

Further findings

False-positive diffusion restriction

Occurred only in small gonads; histologically Leydig cell hyperplasia

Original publication

Gonadal MRI in complete androgen insensitivity syndrome: pathologic correlation and low-risk features. J Clin Endocrinol Metab. Published 11 August 2026. doi:10.1210/clinem/dgag317

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.